Analysts' Actions: JDSU C ALL ANF BIDU

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Allstate ( ALL) downgraded at FBR from Outperform to Market Perform, FBR Capital said. $40 price target Stock is already pricing in lower catastrophe losses.

Abercrombie & Fitch ( ANF) rated new Underperform at Credit Suisse. $32 price target. Turnaround is not imminent as promotional activity remains high.

Alliant Techsystems ( ATK) downgraded at Jefferies to Hold from Buy, Jefferies said. $56 price target. Several catalysts have past.

Aurizon Mines ( AZK) upgraded to buy at TheStreet Ratings

Black Diamond ( BDE) downgraded to hold at TheStreet Ratings

Baidu ( BIDU) downgraded at Jefferies to Hold from Buy, Jefferies said. $125 price target. Search traffic market share shift.

Citigroup ( C) downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. $33 price target. Stocks has rallied 30% since July, but the company lacks near-term catalysts.

CH Robinson ( CHRW) upgraded at Sterne Agee to Buy, Sterne Agee said. $65 price target. Estimates also boosted, as margin fundamentals are improving.

Forum Energy ( FET) downgraded at FBR from Outperform to Market Perform, FBR Capital said. Valuation call, based on a $26 price target.

Finish Line ( FINL) upgraded at Sterne Agee from Underperform to Neutral, Sterne Agee said. Estimates also boosted, given the impact of the Macy's deal.

Fifth Third ( FITB) downgraded at KBW from Outperform to Market Perform, Keefe, Bruyette & Woods said. Valuation call, based on a $17 price target.

Healthcare Services Group ( HCSG) rated new Buy at UBS. $27 price target. Market leader in significantly underpenetrated market.

JDS Uniphase ( JDSU) rated new Neutral at Lazard. Company is hurt by limited macro visibility.

Allscripts ( MDRX) upgraded ISI to Buy. $14.50 price target. Company is a potential takeover target.

ServiceNow ( NOW) downgraded at UBS to Sell from Neutral, UBS said. $28 price target. Valuation call.

Plum Creek ( PCL) downgraded at DA Davidson to Neutral, DA Davidson said. Valuation call, as the stock is up 22% year-to-date. $45 price target.

Raytheon ( RTN) downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. Valuation call, as the stock is up 18% year-to-date. $56 price target.

Boston Beer ( SAM) downgraded at UBS to Sell from Neutral, UBS said. $96 price target. New product distribution stalls, downside risk to estimates.

Molson Coors ( TAP) downgraded at Morgan Stanley from Equal-weight to Underweight, Morgan Stanley said. $45 price target. Stock is up 18% year-to-date, but the company is growing slower than its peers.

Tibco ( TIBX) rated new Neutral at Nomura. Valuation call, based on a $33 price target.

STOCK COMMENTS / EPS CHANGES

Acuity ( AYI) target raised at Oppenheimer. Shares of AYI now seen reaching $66, Oppenheimer said. Improving order rates. Perform rating.

General Cable ( BGC) numbers increased at Keybanc. BGC estimates were raised through 2013, Keybanc said. Alcan purchase should add to earnings. Buy rating and new $37 price target.

Cabot ( CBT) numbers lowered at Jefferies. Shares of CBT now seen reaching $47, Jefferies said. Estimates also lowered on likely soft note in Q4. Buy rating.

EMC ( EMC) estimates, target upped at Cantor. EMC estimates were boosted through 2013, Cantor Fitzgerald said. Company is seeing better high-end performance lower input costs. Buy rating and new $31 price target.

Facebook ( FB) numbers lowered at Oppenheimer. Shares of FB now seen reaching $27, Oppenheimer said. Estimates also lowered on dramatic impact of mobile. Outperform rating.

Finish Line ( FINL) numbers raised at Credit Suisse. Shares of FINL now seen reaching $23, according to Credit Suisse. Estimates also increased, as higher sales are driving margin expansion. Neutral rating.

IBM ( IBM) estimates, target raised at Deutsche. Shares of IBM now seen reaching $240, according to Deutsche Bank. Estimates also increased, as hardware growth should re-accelerate in the near term. Buy rating.

Eli Lilly ( LLY) numbers raised at Credit Suisse. Shares of LLY now seen reaching $54, according to Credit Suisse. Estimates also increased, given higher expected Ramucirumab sales. Outperform rating.

Lowe's ( LOW) estimates, target boosted at Morgan Stanley. Shares of LOW now seen reaching $33, according to Morgan Stanley. Estimates also upped, given higher expected home prices. Overweight rating.

Lam Research ( LRCX) numbers cut at Credit Suisse. LRCX estimates were reduced through 2013, Credit Suisse said. Company is exposed to lower memory demand. Outperform rating and new $38 price target.

McCormick ( MKC) estimates, target boosted at Credit Suisse. Shares of MKC now seen reaching $61, according to Credit Suisse. Estimates also upped, given the company's new guidance. Neutral rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

When Maids Quit to Trade Stocks

When Maids Quit to Trade Stocks

Market Rides a Chinese Seesaw

Market Rides a Chinese Seesaw

NetScout, Danaher Postpone Deal's Closing Date to Give Regulators More Time

4 Big-Volume Stocks to Trade for Breakouts: Big Lots, Fresh Market and More

JDS Uniphase (JDSU) Stock Gains on Competitor's Quarterly Results and Strong Guidance